Hims and Hers Health's compounded Wegovy pill offering fuels market jitters

Core Viewpoint - Hims & Hers is launching compounded versions of Novo Nordisk's Wegovy pill at an introductory price of $49 per month, raising concerns about margin protection for Novo and Eli Lilly as lower-cost alternatives enter the market [1] Company Reactions - David Wagner from Aptus Capital Advisors notes that the GLP-1 market is experiencing an "arms race" for market share and pricing, suggesting that while Lilly remains dominant, any dips in share prices could present buying opportunities [2] - Brian Mulberry from Zacks Investment Management believes the new pill form of GLP-1 will significantly expand the market, allowing both Lilly and Novo to achieve strong revenue growth, while Hims & Hers' choice of the Novo version indicates its growing distribution capabilities [3] - Michael Nedelcovych from TD Cowen highlights that compounding allows for the creation of copycat versions of branded drugs with minor tweaks, which could lead to significant market implications for GLP-1 products [3] Legal and Regulatory Concerns - Markus Manns from Union Investment expresses concerns about the legality of Hims & Hers' move, questioning how long it will take Novo to respond and whether the FDA will intervene, adding uncertainty to the obesity investment narrative [4] - Karen Andersen from Morningstar raises doubts about the clarity and enforcement of laws protecting branded drugs, suggesting that if Hims is allowed to proceed, it could lead to further compounded drug launches once Lilly's orforglipron receives approval [4]